Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 885

Sort by

Sort Order Select

Journal Articles

One step at a time

Hélène Schoemans, Per Ljungman

Blood (2021) 138 (14): 1208–1209.

https://doi.org/10.1182/blood.2021013434

Published: 2021

Journal Articles

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood (2021) 138 (9): 811–814.

https://doi.org/10.1182/blood.2021012443

Published: 2021

Includes: Supplemental data

Journal Articles

Introduction to a review series on pathophysiology and treatment of acute GVHD

Robert Zeiser

Blood (2020) 136 (4): 375–376.

https://doi.org/10.1182/blood.2019004271

Published: 2020

Journal Articles

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Carlijn Voermans, Mette D. Hazenberg

Blood (2020) 136 (4): 410–417.

https://doi.org/10.1182/blood.2019000951

Published: 2020

Journal Articles

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Surbhi Sidana, MD, Gita Thanarajasingam, MD, Joan Griffin, PhD, Carrie A. Thompson, MD, Michelle Burtis, Rahma Warsame, MD, Jonas Paludo, MD, Andrea Cheville, Morie A Gertz, MD, Angela Dispenzieri, MD, Jose Villasboas, MD, Stephen M Ansell, MD PhD, S. Vincent Rajkumar, MD, Kathleen J Yost, PhD, N. Nora Bennani, MD, Mustaqeem Siddiqui, MD, Yi Lin, MD PhD, Shaji K. Kumar, MD, Amylou C. Dueck, PhD

Blood (2019) 134 (Supplement_1): 794.

https://doi.org/10.1182/blood-2019-121715

Published: 2019

Journal Articles

Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Erythroid Cells Derived from Sickle Cell Disease Patients

Samuel Lessard, PhD, Pauline Rimmele, PhD, Hui Ling, PhD, Kevin Moran, MSc, Benjamin Vieira, BS, Yi-Dong Lin, PhD, Vu Hong, PhD, Andreas Reik, PhD, Denny Dang, Naoya Uchida, MD, John F. Tisdale, MD, Pablo Rendo, MD, Ahmed Daak, PhD, Alexandra Hicks, PhD

Blood (2019) 134 (Supplement_1): 974.

https://doi.org/10.1182/blood-2019-126048

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients

Ying Wang, Jiang Cao, MD, Yan Zhiling, MD, Jianlin Qiao, PhD, Deipeng Li, MD, Zhenyu Li, MD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 1301.

https://doi.org/10.1182/blood-2019-127808

Published: 2019

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, MD, Zhen-Huan Hu, MPH, Yiyun Zhang, PhD, Manali Kamdar, MD, Monalisa Ghosh, Premal Lulla, MBBS, Joshua Sasine, MD PhD, Miguel-Angel Perales, MD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Margit Jeschke, PhD, Lan Yi, PhD, Raghav Chawla, MD PhD, Lida Pacaud, Mary M. Horowitz, Eric Bleickardt, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 766.

https://doi.org/10.1182/blood-2019-130983

Published: 2019

Journal Articles

Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients

Loic Ysebaert, MD PhD, Anne-Sophie Michallet, MD PhD, Fontanet Bijou, MD, Aline Clavert, MD, Anne Quinquenel, MD, Anne Calleja, Romain Guieze, MD PhD, Emmanuelle Ferrant, MD, Annie Brion, Kamel Laribi, MD

Blood (2019) 134 (Supplement_1): 1741.

https://doi.org/10.1182/blood-2019-122318

Published: 2019

Journal Articles

Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups

Ana M Metelo, PhD, Ieuan Walker, BSc, MSc, MBBS, Agnieszka Jozwik, PhD, Charlotte Graham, MRCP, BSc, MBBS, Charlotte Attwood, BMedSci, MBBS, MRCP, FRCPath, Katy Sanchez, BSc, MSc, Alan Dunlop, BSc, MSc, Kirsty Cuthill, FRCPath,MBBS,MRCP,PhD, Carmel Rice, FRACP, FRCPA, MBBS, Matthew Streetly, MD, Trevor Bentley, BSc, Bijan Boldajipour, PhD, Cesar Sommer, PhD, Barbra Sasu, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 1834.

https://doi.org/10.1182/blood-2019-124312

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD

Blood (2019) 134 (Supplement_1): 1902.

https://doi.org/10.1182/blood-2019-130990

Published: 2019

Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD

Blood (2019) 134 (Supplement_1): 1848.

https://doi.org/10.1182/blood-2019-127893

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 50.

https://doi.org/10.1182/blood-2019-125372

Published: 2019

Journal Articles

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Wenqun Zhang, MD, Bo Hu, MD, Ling Jing, MD, Jing Yang, MD, Shan Wang, MD, Yang Liu, MD, Juan Du, MD, Yaoliang Ren, MD, Yonghong Zhang, MD

Blood (2019) 134 (Supplement_1): 1945.

https://doi.org/10.1182/blood-2019-125753

Published: 2019

NARROW

One step at a time

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Introduction to a review series on pathophysiology and treatment of acute GVHD

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Erythroid Cells Derived from Sickle Cell Disease Patients

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients

Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only